Journal of General Virology 2013-05-01

Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

Shigeyoshi Harada, Kazuhisa Yoshimura, Aki Yamaguchi, Samatchaya Boonchawalit, Keisuke Yusa, Shuzo Matsushita

Index: J. Gen. Virol. 94(Pt 5) , 933-43, (2013)

Full Text: HTML

Abstract

The initiation of drug therapy results in a reduction in the human immunodeficiency virus type 1 (HIV-1) population, which represents a potential genetic bottleneck. The effect of this drug-induced genetic bottleneck on the population dynamics of the envelope (Env) regions has been addressed in several in vivo studies. However, it is difficult to investigate the effect on the env gene of the genetic bottleneck induced not only by entry inhibitors but also by non-entry inhibitors, particularly in vivo. Therefore, this study used an in vitro selection system using unique bulk primary isolates established in the laboratory to observe the effects of the antiretroviral drug-induced bottleneck on the integrase and env genes. Env diversity was decreased significantly in one primary isolate [KP-1, harbouring both CXCR4 (X4)- and CCR5 (R5)-tropic variants] when passaged in the presence or absence of raltegravir (RAL) during in vitro selection. Furthermore, the RAL-selected KP-1 variant had a completely different Env sequence from that in the passage control (particularly evident in the gp120, V1/V2 and V4-loop regions), and a different number of potential N-glycosylation sites. A similar pattern was also observed in other primary isolates when using different classes of drugs. This is the first study to explore the influence of anti-HIV drugs on bottlenecks in bulk primary HIV isolates with highly diverse Env sequences using in vitro selection.


Related Compounds

Related Articles:

Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.

2014-11-20

[Int. J. Pharm. 475(1-2) , 191-7, (2014)]

Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.

2012-03-15

[Cell Cycle 11(6) , 1174-82, (2012)]

Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome?

2012-05-01

[Nephrol. Dial. Transplant. 27(5) , 1698-701, (2012)]

Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis.

2013-06-15

[J. Neuroimmunol. 259(1-2) , 55-65, (2013)]

Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.

2012-09-01

[J. Pharm. Sci. 101(9) , 3199-213, (2012)]

More Articles...